Ionis Pharmaceuticals Inc. ($IONS) recently marked a significant milestone by launching Zanvastro, its first independently developed neurology drug aimed at treating Alexander disease, a rare and progressive neurological disorder. This FDA-approved treatment offers the first disease-modifying option for patients, though its high price tag of $285,000 per dose and the very limited patient population present challenges for widespread adoption. Despite these hurdles, Ionis anticipates Zanvastro could generate over $100 million in peak annual sales, signaling a promising new revenue stream and potentially reducing perceived risks around its broader neurology pipeline.
On the other hand, Ionis is also navigating setbacks tied to its cardiovascular drug pelacarsen, which was licensed to Novartis. Novartis recently announced that pelacarsen failed to meet the primary endpoint in a late-stage Phase 3 trial aimed at reducing cardiovascular events, despite successfully lowering lipoprotein(a) levels. This outcome has dampened expectations for what was once forecasted as a multibillion-dollar opportunity. The clinical failure has financial implications for Ionis, especially as Royalty Pharma, which provided Ionis with funding tied to pelacarsen royalties, now shifts focus toward other assets like Spinraza. While pelacarsen’s setback is a blow, it does not disprove the potential benefits of lowering Lp(a), and Ionis continues to advance its pipeline amid these mixed developments.
Markets are currently closed and will reopen tomorrow at 9:30 AM ET, where investors will likely watch closely how these contrasting developments influence Ionis Pharmaceuticals’ stock trajectory.
Did you know?
The stock market has historically rewarded companies that successfully bring first-of-their-kind treatments to market, even in ultra-rare diseases, because of the high value placed on innovation and unmet medical needs.
Disclaimer
This content is for entertainment and discussion purposes only. It is based on publicly available headlines and social media commentary, which can be messy and ever-evolving. We are not financial advisors, and this is not investment advice. The publisher may hold positions in securities mentioned. We aim to keep things accurate—if you catch something off, please let us know.
Powered by - Trading Watch Premium
This data is 100% free and is made possible by our Monthly Supporters.
No Comments